# Granules India (NSE: GRANULES) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/GRANULES · Pivot · prices to 21 Oct 2026

Granules India (NSE: GRANULES) closed at ₹807.05 on 21 Oct 2026. With a market capitalisation of ₹19,894 Cr, it ranks 361st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

At its last close the stock traded at 32.8× trailing earnings, against a return on equity of 11.7% in FY26. Over the past year the share price has risen 41.1%. Its 52-week range is ₹529.85 (25 Nov 2025) to ₹923.65 (15 Sep 2026); the last close is 12.6% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹11 Cr (+49.3% year on year) and net profit −₹1 Cr (−267.9%), on a consolidated basis. Promoters held 38.02% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹807.05 |
| Market cap | ₹19,894 Cr |
| P/E (trailing) | 32.8 |
| ROE | 11.7% (FY26) |
| ROCE | 16.2% (FY26) |
| Debt to equity | 0.26 |
| 52-week high | ₹923.65 (15 Sep 2026) |
| 52-week low | ₹529.85 (25 Nov 2025) |
| 1-year return | +41.1% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹11 Cr | +49.3% | −₹1 Cr | −267.9% | −₹0.84 |
| Q3 FY26 | ₹16 Cr | +64.0% | ₹1 Cr | +316.7% | ₹1.09 |
| Q2 FY26 | ₹15 Cr | +71.5% | ₹1 Cr | +880.0% | ₹0.52 |
| Q1 FY26 | ₹14 Cr | +38.6% | ₹0 Cr | +20.6% | ₹0.22 |
| Q4 FY25 | ₹8 Cr | — | ₹1 Cr | — | ₹0.52 |
| Q3 FY25 | ₹10 Cr | — | ₹0 Cr | — | ₹0.20 |
| Q2 FY25 | ₹9 Cr | — | ₹0 Cr | — | ₹0.07 |
| Q1 FY25 | ₹10 Cr | — | ₹0 Cr | — | ₹0.20 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY26 | ₹5,366 Cr | ₹595 Cr |
| FY25 | ₹4,482 Cr | ₹502 Cr |
| FY24 | ₹4,506 Cr | ₹405 Cr |
| FY23 | ₹4,512 Cr | ₹517 Cr |
| FY22 | ₹3,765 Cr | ₹413 Cr |
| FY21 | ₹3,238 Cr | ₹549 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 38.02%
- Foreign institutions: 17.50%
- Domestic institutions: 16.11%
- Non-institutions: 28.38%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Procter Gamble](https://app.pivotnow.in/stock/PGHH) | ₹7,110.00 | ₹23,080 Cr | 26.9 | 62.3% |
| [Piramal Phytoca](https://app.pivotnow.in/stock/PIRPHYTO) | — | ₹21,083 Cr | — | — |
| [SAGILITY](https://app.pivotnow.in/stock/SAGILITY) | ₹43.95 | ₹20,574 Cr | 22.2 | 9.6% |
| [Indraprastha](https://app.pivotnow.in/stock/IGL) | ₹142.29 | ₹19,921 Cr | 12.9 | 27.0% |
| [Cohance Lifesciences](https://app.pivotnow.in/stock/COHANCE) | ₹456.50 | ₹17,464 Cr | 97.8 | 15.8% |
| [Pfizer](https://app.pivotnow.in/stock/PFIZER) | ₹3,805.50 | ₹17,409 Cr | 24.1 | 17.2% |

## Questions and answers

### What is the share price of Granules India today?

Granules India (NSE: GRANULES) last closed at ₹807.05 on 21 Oct 2026. Its 52-week high is ₹923.65 and its 52-week low is ₹529.85.

### What is the market cap of Granules India?

Granules India's market capitalisation is ₹19,894 Cr (₹19,894 Cr) at the 19 Oct 2026 close, ranking 361st among the NSE companies Pivot tracks.

### What is the P/E ratio of Granules India?

Granules India trades at a trailing P/E of 32.8. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 24.1.

### What is the ROE and ROCE of Granules India?

Return on equity was 11.7% in FY26 and return on capital employed was 16.2% in FY26 (consolidated figures).

### Is Granules India a debt-free company?

No. Granules India's debt-to-equity ratio was 0.26 in FY26, with total debt of ₹297 Cr.

### What were Granules India's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Granules India reported revenue of ₹11 Cr, +49.3% year on year, and net profit of −₹1 Cr, −267.9% year on year.

### How has Granules India stock performed over the last year?

Granules India's share price has risen 41.1% over the past year, −8.6% over three months and −8.0% over one month, to the 19 Oct 2026 close.

### What is the shareholding pattern of Granules India?

As of 30 Jun 2026: promoters 38.02%, foreign institutions 17.50%, domestic institutions 16.11%, non-institutions 28.38%.

### Who are Granules India's competitors?

The listed Pharma & Healthcare companies closest to Granules India by market cap are Procter Gamble, Piramal Phytoca, SAGILITY, Indraprastha, Cohance Lifesciences and Pfizer.

### Is Granules India a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Granules India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GRANULES against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.